News & Insights

RxC actively researches and publishes its point of view on key issues impacting the pharma and biotech industries.  We welcome your input on our pieces.  To be notified when we publish something new, please sign up for our updates newsletter.

Subscribe to Our Updates

RxC International Transforms Biopharmaceutical Life Cycle Management Planning with RxC ProLOGS™ Solution

RxC International announced today the launch of its RxC ProLOGS™ pharmaceutical life cycle management planning solution.  RxC ProLOGS incorporates in-depth market research, innovative concept development, advanced analytics, cross-functional client input, and industry best practices to produce actionable insights for maximizing product value.

Monthly Gene Therapy Business Review - February 2018

March 13, 2018

Top Stories for February 2018:

  1. Lessons Learned from Hepatitis C: Intense Competition Requires Careful Commercial Planning for Sickle Cell Gene Therapies
  2. Gene Therapy IP, Manufacturing, and Delivery Pathways Still Evolving
  3. FDA Moving Forward with its Role in Advancing a Modern Framework for Gene Therapy

Read about these developments and our commercial insights into the ongoing evolution of the gene therapy market.

Monthly Gene Therapy Business Review - January 2018

February 7, 2018

This month, the most noteworthy gene therapy stories include:

  • Still Learning What We Don’t Know: Gene Therapy Market Impacted by Safety Concerns
  • Headline “Gene Therapy Could Make Cancer Care More Unequal” Probably Not True

  • China’s Quest for Gene Therapy Success

  • Answering ICER: Spark CEO Offers Rationale for Luxturna Price

A little earlier than expected, Spark’s announces Luxturna pricing, $850k

January 7, 2018

RxC International has evaluated the Luxturna clinical story and its market opportunity, including critical questions regarding this highly-watched commercial launch.  Here's what you need to know.

Monthly Gene Therapy Business Review - December 2017

Monthly Gene Therapy Business Review - December 2017

January 2, 2018

This month, the most noteworthy gene therapy stories include:

  • First Mover Advantage? Gilead Blazes Trail for Competition
  • Newly-Published Yescarta Study Raises Safety Concerns

  • Results from Hemophilia Gene Therapy Studies Prompt Pricing Questions...Again

Read about these developments and our commercial insights into the ongoing evolution of the gene therapy market.

Monthly Gene Therapy Business Review - November 2017

December 6, 2017

November saw some important moments in gene therapy.  We have summarized the most noteworthy and included the remaining in our news and updates sections.

SlideShare: Avoiding the Most Common  Challenges Faced by Existing Pharma Co-Promotions

December 5, 2017

Existing pharma co-promotions face challenges that can threaten their success and longevity if not addressed. Learn about the these challenges and methods our expert co-promotion team has applied to remedy them.

RxC International Gene Therapy Newsletter

Landmark Month Sees Second Gene Therapy Approved and Other Wins

November 9, 2017

October was a landmark month for gene therapies with the approval of the second-ever gene therapy in the US, Yescarta (axicabtagene ciloleucel) from Kite and Gilead.  The prior approval of Novartis’ Kymriah is more proof that gene therapies are set to shake up the pharma industry.  Gene therapies saw other wins as Luxturna, Spark’s treatment for Leber congenital amaurosis, received the FDA’s recommendation for approval and Bluebird Bio’s interim data report for its gene therapy Lenti-D to treat cerebral adrenoleukodystrophy showed promising results.

RxC International Product Lifecycle Management Planning

Effective Pharmaceutical Life Cycle Management Planning: Optimizing Product Value over a Drug's Lifespan

November 9, 2017

Developing an effective drug life cycle management plan is critical for maximizing the value of a pharma product over the course of its commercial lifespan. Drawing from our deep expertise of pharmaceutical product lifecycle management, RxC International has identified key success factors and industry best practices as well as common pitfalls to avoid when developing and implementing LCM plans.

Partnering for Successful Life Cycle Management: 5 Reasons to Seek Outside Help

October 31, 2017

Pharmaceutical companies with effective Life Cycle Management (LCM) planning typically work with outside partners to develop and execute LCM plans.  Working with a third-party partner adds outside thinking and best practices to an organization.  “When you can [bring] in the experience that you need, you’ll benefit from the hard work that others have done, shorten your time to market for new products, and introduce new talent to your company,” writes Madeline Bennett of The Telegraph.

The 8 Most Common (and Costly!) Life Cycle Management Pitfalls (and How to Avoid Them)

September 27, 2017

Understanding the critical success factors of Life Cycle Management (LCM) planning helps pharmaceutical companies avoid common life cycle pitfalls that can lead to sub-optimal life cycle plans or ineffective implementations.  Companies that don’t optimize the life cycle management process and develop innovative strategies to meet the demands of today’s pharmaceutical landscape generally experience lower returns than their more proactive counterparts.

RxC International Common Copromotion Challenges

9 Common Challenges for Existing Co-Promotions

September 14, 2017

Successfully optimizing co-promotional agreements relies upon governance, brand management, and performance management. Yet, despite good intentions from each party, challenges can arise in a co-promotional agreement that threaten its longevity and overall success.  In our experience, preventing or overcoming challenges in existing co-promotions usually requires assistance from a third party like RxC International.  Below are the nine most common challenges we have encountered during our extensive experience with co-promotion programs.

RxC International Avoiding Drug Value Erosion with Effective Life Cycle Management

How to Avoid Pharmaceutical Value Erosion: 5 Critical Components of a Highly Effective Life Cycle Management Process

September 7, 2017

A comprehensive Life Cycle Management (LCM) process is essential to developing pharmaceutical life cycle plans that deliver maximum value over the life of pipeline and marketed products. Ensuring that the life cycle process is objectively and consistently executed enables organizations to fully explore all potential concepts, foster collaborative thinking, and uncover more innovative opportunities. Life sciences companies with multiple products across several therapeutic areas can benefit from a consistent approach that allows management to make effective comparisons across the organizational portfolio and allocate resources accordingly.

Bradley Kozar RxC International.jpg

Bradley Kozar to Bring Market Access Expertise to RxC International as Strategy Partner

September 6, 2017

MORRISTOWN, NJ, RxC International, a premier life sciences management consulting firm, announced today that Bradley K. Kozar has joined the firm as a Strategy Partner. Brad is a payer strategy and market access consulting executive with significant consulting/agency and pharmaceutical industry experience. “Brad is a leading expert in managed markets - he has led many successful biopharma product launches and has been instrumental in helping his clients achieve more favorable market access through better formulary placement and reimbursement.  We are excited to have Brad joining us to provide our clients with a more integrated offering by addressing market access within our core services of corporate strategy, new product strategy and commercial excellence,” said Subbarao Jayanthi, Managing Partner of RxC International.

RxC BioPharma Life Cycle Management

The Importance of Early Life Cycle Management

August 1, 2017

Companies must implement effective Life Cycle Management (LCM) strategies to build more value into products while they are still in development.  LCM includes identifying and prioritizing multiple potential indications and formulations while strategically planning their development and launch timing and sequence.  Competitive companies must also direct sufficient resources to a strong LCM process for their pipeline and marketed products.

Optimizing Co-Promotion Effectiveness Shortcut

Optimizing Co-Promotion Effectiveness

June 28, 2017

As the complexity and investment for successfully marketing a prescription drug or biologic rises, many companies seek to de-risk their commercialization effort by joining forces with a partner biopharma company.  Co-promotions, or the formal relationship established between two companies to combine resources for a more effective promotion of a product, are becoming increasingly common in the biopharma industry. While co-promotions are structured with the right intent, these agreements require careful consideration of several key strategic and operational issues in order to achieve optimal effectiveness.

RxC Gene Therapy Blog Post

Gene Therapies: Pathways for Commercial Success

June 1, 2017

Gene therapies are poised to enter the US healthcare system within the next 1-2 years as viable treatment options for a variety of diseases. In response to this burgeoning opportunity, the Institute for Clinical and Economic Review (ICER) convened a policy summit and recently released a report on the potential value and challenges of gene therapy treatments